

# Harjeet Singh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/629095/publications.pdf>

Version: 2024-02-01

21  
papers

1,670  
citations

687363

13  
h-index

794594

19  
g-index

21  
all docs

21  
docs citations

21  
times ranked

2525  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. <i>Cancer Research</i> , 2015, 75, 3505-3518.	0.9	327
2	Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E7788-E7797.	7.1	320
3	Redirecting Specificity of T-Cell Populations For CD19 Using the <i>Sleeping Beauty</i> System. <i>Cancer Research</i> , 2008, 68, 2961-2971.	0.9	232
4	Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using <i>Sleeping Beauty</i> System and Artificial Antigen Presenting Cells. <i>PLoS ONE</i> , 2013, 8, e64138.	2.5	143
5	A new approach to gene therapy using <i>Sleeping Beauty</i> to genetically modify clinical-grade T cells to target <i>CD</i> 19. <i>Immunological Reviews</i> , 2014, 257, 181-190.	6.0	121
6	Gene Therapy with the <i>Sleeping Beauty</i> Transposon System. <i>Trends in Genetics</i> , 2017, 33, 852-870.	6.7	92
7	Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 473-482.	3.4	85
8	Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. <i>Clinical Cancer Research</i> , 2015, 21, 3241-3251.	7.0	83
9	Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia. <i>Leukemia</i> , 2021, 35, 3282-3286.	7.2	61
10	Redirecting Specificity of T cells Using the <i>Sleeping Beauty</i> System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors. <i>PLoS ONE</i> , 2016, 11, e0159477.	2.5	50
11	Automated profiling of individual cell-cell interactions from high-throughput time-lapse imaging microscopy in nanowell grids (TIMING). <i>Bioinformatics</i> , 2015, 31, 3189-3197.	4.1	45
12	Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. <i>Oncogene</i> , 2018, 37, 3686-3697.	5.9	45
13	Combination Immunotherapy with NY-ESO-1-Specific CAR+ T Cells with T-Cell Vaccine Improves Anti-Myeloma Effect. <i>Blood</i> , 2016, 128, 3366-3366.	1.4	14
14	TIMING 2.0: high-throughput single-cell profiling of dynamic cell-cell interactions by time-lapse imaging microscopy in nanowell grids. <i>Bioinformatics</i> , 2019, 35, 706-708.	4.1	12
15	Designed improvement to T-cell immunotherapy by multidimensional single cell profiling. , 2021, 9, e001877.		12
16	Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies. <i>Blood</i> , 2015, 126, 862-862.	1.4	11
17	Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1759-1769.	2.0	9
18	Defining potency of CAR <sup>+</sup> T cells: Fast and furious or slow and steady. <i>Oncolmmunology</i> , 2019, 8, e1051298.	4.6	4

#	ARTICLE	IF	CITATIONS
19	Very Rapid Production of CAR+ T-Cells upon Non-Viral Gene Transfer Using the Sleeping Beauty System. Blood, 2016, 128, 2807-2807.	1.4	2
20	Efficacy of "Off-the-Shelf"™, Commercially-Available, Third-Party Mesenchymal Stem Cells (MSC) in Ex Vivo Cord Blood (CB) Co-Culture Expansion.. Blood, 2007, 110, 4106-4106.	1.4	2
21	Rapid Personalized Manufacture (RPM) of Sleeping Beauty System-Generated NY-ESO-1-Specific TCR-T Cells Co-Expressing Membrane-Bound IL-15 Yields Anti-Tumor Responses. Blood, 2019, 134, 3218-3218.	1.4	0